Details for Patent: 11,819,480
Which drugs does patent 11,819,480 protect, and when does it expire?
Patent 11,819,480 protects ORSERDU and is included in one NDA.
This patent has eighty-nine patent family members in fourteen countries.
Summary for Patent: 11,819,480
| Title: | Methods for treating cancer |
| Abstract: | Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant estrogen receptor alpha positive cancer or a mutant estrogen receptor alpha positive cancer. The methods entail administering to the subject a therapeutically effective amount of RAD1901 having the structure:or a salt or solvate thereof. |
| Inventor(s): | Fiona GARNER, Gary Hattersley |
| Assignee: | Radius Pharmaceuticals Inc |
| Application Number: | US16/985,021 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,819,480
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-001 | Jan 27, 2023 | RX | Yes | No | 11,819,480 | ⤷ Start Trial | TREATMENT OF AN ER-POSITIVE BREAST CANCER | ⤷ Start Trial | ||||
| Stemline Therap | ORSERDU | elacestrant hydrochloride | TABLET;ORAL | 217639-002 | Jan 27, 2023 | RX | Yes | Yes | 11,819,480 | ⤷ Start Trial | TREATMENT OF AN ER-POSITIVE BREAST CANCER | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,819,480
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016256469 | ⤷ Start Trial | |||
| Australia | 2016256470 | ⤷ Start Trial | |||
| Australia | 2016256471 | ⤷ Start Trial | |||
| Brazil | 112017023228 | ⤷ Start Trial | |||
| Brazil | 112017023233 | ⤷ Start Trial | |||
| Brazil | 112017023269 | ⤷ Start Trial | |||
| Canada | 2984195 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
